Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line chemotherapy with or without bevacizumab after first-line bevacizumab in metastatic colorectal cancer
2007-002886-11Phase 3Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: progression-free survival. Started Feb 2008; status: active.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2007-002886-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002886-11.